Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Agreements reached under this partnership
Business alliance4576D.Western Therapeutics Institute, Inc.
Alliance partnerTerrain Pharmaceuticals
About the partner
Business DescriptionA U.S. specialty pharmaceutical company with more than 10 years of experience developing and marketing topical analgesics. Through a nationwide distribution network covering independent retail pharmacies, specialty pharmacies and healthcare institutions, it markets prescription and over-the-counter topical patches and semisolid formulations, including products based on lidocaine and NSAIDs.
LocationReno, Nevada, U.S.
Impact on Business Performance
Because the revenue outlook for the product remains uncertain, there will be no change to the earnings forecast for the fiscal year ending December 2026 as a result of this matter. The company will promptly disclose any impact once it becomes known.
Alliance start datePlans to proceed with preparations for a launch in the second half of 2026
| Item | Details |
|---|---|
| Name of alliance partner | Terrain Pharmaceuticals |
| Alliance partner's business activities | A U.S. specialty pharmaceutical company with more than 10 years of experience developing and marketing topical analgesics. Through a nationwide distribution network covering independent retail pharmacies, specialty pharmacies and healthcare institutions, it markets prescription and over-the-counter topical patches and semisolid formulations, including products based on lidocaine and NSAIDs. |
| Alliance partner's location | Reno, Nevada, U.S. |
| Type of alliance | Business alliance |
| Alliance start date | Plans to proceed with preparations for a launch in the second half of 2026 |
| Impact on Business Performance | Because the revenue outlook for the product remains uncertain, there will be no change to the earnings forecast for the fiscal year ending December 2026 as a result of this matter. The company will promptly disclose any impact once it becomes known. |
Items this document does not state (17)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeDetails of the allianceNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the revenue outlook for Bondlido remains uncertain, the company has not revised its earnings forecast for the fiscal year ending December 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.